Silurian Pharmaceuticals- Translating Marine Biomedical Discoveries to Medicine
Silurian Pharmaceuticals, Inc. was founded in July 2014.
The company licensed the IP for brevenal and other k. brevis related discoveries from the University of North Carolina, Wilmington (UNCW), Marine Biotechnology in North Carolina (MARBIONC) Center.
The company is developing its first drug, brevenal, for the treatment of cystic fibrosis (CF).
At later stages, brevenal will be developed for the treatment of advanced chronic obstructive pulmonary disease(COPD).
The company also holds patents for the development of additional compounds from K. brevis platform.